Emerald Advisers LLC Increases Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Emerald Advisers LLC grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 416,866 shares of the biotechnology company’s stock after buying an additional 41,000 shares during the period. Blueprint Medicines accounts for 1.4% of Emerald Advisers LLC’s portfolio, making the stock its 16th biggest position. Emerald Advisers LLC owned approximately 0.66% of Blueprint Medicines worth $36,359,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in BPMC. Torray Investment Partners LLC grew its stake in Blueprint Medicines by 1.1% in the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after purchasing an additional 186 shares during the period. Franklin Resources Inc. grew its stake in Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after purchasing an additional 265 shares during the period. Hillsdale Investment Management Inc. grew its stake in Blueprint Medicines by 0.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company’s stock worth $4,433,000 after purchasing an additional 310 shares during the period. Quarry LP purchased a new stake in Blueprint Medicines in the third quarter worth $32,000. Finally, Van ECK Associates Corp grew its stake in Blueprint Medicines by 48.2% in the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 363 shares during the period.

Insider Transactions at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 15,161 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the transaction, the director now owns 152,396 shares in the company, valued at $16,691,933.88. The trade was a 9.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,334 shares of company stock worth $3,103,512. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock opened at $88.72 on Friday. The firm has a market cap of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The stock has a 50 day moving average of $99.47 and a 200 day moving average of $93.88. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, research analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BPMC. Scotiabank began coverage on Blueprint Medicines in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 price target on the stock. Wolfe Research began coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an “outperform” rating on the stock. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. JMP Securities reissued a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.